(NASDAQ: ATRA) Atara Biotherapeutics's forecast annual revenue growth rate of 306.09% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Atara Biotherapeutics's revenue in 2024 is $8,573,000.On average, 2 Wall Street analysts forecast ATRA's revenue for 2024 to be $8,236,980,462, with the lowest ATRA revenue forecast at $2,508,931,015, and the highest ATRA revenue forecast at $13,965,029,910.
In 2025, ATRA is forecast to generate $1,909,747,680 in revenue, with the lowest revenue forecast at $1,909,747,680 and the highest revenue forecast at $1,909,747,680.